Ligand Pharmaceuticals
Preço: 255.54Empresa e modelo de negócios
Ligand Pharmaceuticals is a biotechnology company focused on developing and commercializing technologies that enhance drug discovery and development. Its core products include a range of proprietary technologies and partnered programs that facilitate the creation of therapeutics across various disease areas. Major business segments include royalty revenue from partnered products and licensing agreements. The primary revenue sources stem from collaborations with pharmaceutical companies and royalties from sales of drugs utilizing Ligand's technologies.
Perfil de investimento
The investment profile of Ligand Pharmaceuticals is more aligned with value investors, given its current market position and revenue trends. The stock may appeal to those seeking potential long-term appreciation, although recent performance indicates challenges. Investors should consider the company's volatility and risk factors when evaluating their investment horizon.
Métricas fundamentais (experimental)
- EPS (TTM) — lucro por ação dos últimos 12 meses, $
- 7.84 OK
- Receita QoQ — crescimento da receita trimestre contra trimestre
- -13.3% ↓
- Surpresa de EPS
- -11.4% pior que o esperado
- Volatilidade 20d
- 1.8% estável
Acompanhar no portfólio
Gráfico de preço
| Data | Antes | Depois | Motivo |
|---|---|---|---|
| 2026-05-24 02:44 | Vender | Manter | Weak fundamentals and high risk limit upside potential. |
| 2026-05-16 02:46 | Manter | Vender | Weak fundamentals and negative momentum raise concerns. |
| 2026-05-08 15:20 | — | Manter | Weak fundamentals and negative momentum raise concerns. |
| Data | Analista | Action | Alvo | Preço na época |
|---|---|---|---|---|
| 2026-04-30 10:09 | H.C. Wainwright | Preço-alvo elevado | 243 → 289 | 224.86 |
| 2026-04-28 11:36 | RBC Capital | Preço-alvo elevado | 235 → 252 | 241.79 |
| 2026-04-27 18:05 | Stifel Nicolaus | Preço-alvo elevado | 230 → 255 | 241.79 |
Nada ainda